Amgen Inc. Submits SEC Filing

Strategic Insights -

Amgen Inc., a leading biopharmaceutical company, submitted a significant filing with the U.S. Securities and Exchange Commission (SEC) on August 3, 2023. The filing, identified by the SEC file number 0000318154-23-000049, contains 15 documents that provide crucial information about the company's recent events and corporate changes. As a publicly-traded company, Amgen is required to submit regular filings with the SEC to keep investors informed about its progress and any significant developments.

Key Takeaways:

  • Amgen Inc. submitted a Form 8-K filing with the SEC on August 3, 2023, as part of its ongoing commitment to transparency and compliance with regulatory requirements.
  • The filing contains 15 documents that detail various material events and corporate changes, providing investors with crucial information about the company's progress.
  • As a biopharmaceutical company with a SIC code of 2836, Amgen is subject to regular reporting requirements to ensure transparency and accountability to investors.
  • Amgen's filing is a prime example of the importance of SEC filings in maintaining transparency and providing investors with reliable information about publicly-traded companies.
  • The filing also highlights the significance of the current report (Form 8-K) in providing more up-to-date information on material events compared to other forms like 10-Q or 10-K.

Statistics:

  • 1: Amgen Inc. is a biopharmaceutical company with a SIC code of 2836.
  • 15: The number of documents contained in the Form 8-K filing submitted by Amgen Inc. with the SEC on August 3, 2023.
  • 0000318154-23-000049: The SEC file number for Amgen's Form 8-K filing.
  • 3 August 2023: The date that Amgen submitted its SEC filing.

Sources:

  • U.S. Securities and Exchange Commission filing by Amgen Inc. (Form 8-K) on August 3, 2023.
  • [1] NewsRx LLC. News Reporter-Staff News Editor. Biotech Week, 2023 AUG 23.